Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
Tanya Barauskas DorffJeff A LongmateSumanta K PalWalter M StadlerMayer N FishmanUlka N VaishampayanAmol RaoJacek K PinksiJames S HuDavid I QuinnPrimo N LaraPublished in: Cancer (2017)
TRC105 failed to improve PFS when added to bevacizumab. TGFβ warrants further study as a biomarker in RCC. Cancer 2017;123:4566-4573. © 2017 American Cancer Society.